Results 291 to 300 of about 912,795 (359)
Some of the next articles are maybe not open access.
Current Treatment Options in Gastroenterology, 2004
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie D, Straley, Norah A, Terrault
openaire +2 more sources
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie D, Straley, Norah A, Terrault
openaire +2 more sources
Treatment of chronic hepatitis B
Journal of Viral Hepatitis, 2005Summary. In the last years, marked progress has been made in the treatment of chronic hepatitis B. The efficacy of lamivudine, the first nucleoside analogue available, is limited by the high incidence of resistance. Adefovir, which was recently approved has a comparable efficacy with a very low frequency of resistance.
Tarik, Asselah +2 more
openaire +5 more sources
Treatment of chronic hepatitis B
Nature Clinical Practice Gastroenterology & Hepatology, 2006Treatment of chronic hepatitis B has improved substantially over the past five years. Pegylated interferon alpha2a and entecavir have been approved by the FDA and joined the armamentarium of therapies that includes inteferon alpha (IFN-alpha), lamivudine, and adefovir dipivoxil. Several key questions come to mind regarding treatment. Who should receive
Smruti R, Mohanty +2 more
openaire +2 more sources
Interferon in chronic hepatitis B
Antiviral Research, 1994In patients with typical chronic hepatitis B (HBsAg, HBeAg, HBV-DNA-positive), treatment with interferon-alpha must be carried out for 4-6 months on an alternate-day basis and dosage should be not less than 5 million units/square meter of body surface.
G, Saracco, M, Rizzetto, G, Verme
openaire +2 more sources
Prevalence of Hepatic Granulomas in Chronic Hepatitis B
Digestive Diseases and Sciences, 2004An increasing frequency of hepatic granulomas, up to 10%, in chronic hepatitis C patients is reported, and their presence is considered to be a predictor of treatment success. However, there is only one prevalence study on granuloma in chronic hepatitis B, and its significance for treatment outcome is unknown.
Veysel, Tahan +13 more
openaire +4 more sources
Current Opinion in Gastroenterology, 2011
We review here new developments in chronic hepatitis B (CHB) treatment, based on review of published articles between December 2009 and November 2010.It is estimated that two-thirds of US CHB patients have not been identified, evaluated and appropriately treated, largely due to lack of knowledge and awareness of CHB among medical professionals and at ...
Hejun, Yuan, William M, Lee
openaire +2 more sources
We review here new developments in chronic hepatitis B (CHB) treatment, based on review of published articles between December 2009 and November 2010.It is estimated that two-thirds of US CHB patients have not been identified, evaluated and appropriately treated, largely due to lack of knowledge and awareness of CHB among medical professionals and at ...
Hejun, Yuan, William M, Lee
openaire +2 more sources
Annals of Internal Medicine, 1988
Excerpt To the Editor:Perrillo and colleagues (1) make an important contribution to the study of chronic hepatitis B treatment.
openaire +2 more sources
Excerpt To the Editor:Perrillo and colleagues (1) make an important contribution to the study of chronic hepatitis B treatment.
openaire +2 more sources
Management of Chronic Hepatitis B
European Journal of Gastroenterology & Hepatology, 2011Chronic hepatitis B affects 400 million people worldwide. The criteria for initiating and stopping treatment are still under debate in spite of well-established agents for its treatment.
Lai, CL, Yuen, MF
openaire +4 more sources
Treatment of chronic hepatitis B
The Lancet Infectious Diseases, 2001This review updates the treatment of chronic hepatitis B infection. Complete eradication of hepatitis B virus (HBV) is not possible, so the efficacy of treatment has to be assessed by whether it can limit long-term cirrhosis-related complications. We discuss two major groups of treatments--immunomodulators (interferon alfa, thymosin alpha1, therapeutic
Lai, CL, Yuen, MF
openaire +4 more sources
Pathology of Chronic Hepatitis B and Chronic Hepatitis C
Clinics in Liver Disease, 2010Histologic evaluation of the liver is a major component in the medical management and treatment algorithm of patients with chronic hepatitis B (HBV) and chronic hepatitis C (HCV). Liver biopsy in these patients remains the gold standard, and decisions on treatment are often predicated on the degree of damage and stage of fibrosis. This article outlines
openaire +2 more sources